Segment disclosures

Company overview

티에스바이오

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 4 retained observations 4 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Consolidated

Consolidated And Separate Financial Statements

Source dimensions ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis=ifrs-full:ConsolidatedMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-313813391838 KRW20240516Open filing evidence
2023-01-01 – 2023-12-313640012563 KRW20240401Open filing evidence
2023-01-01 – 2023-03-31275810300 KRW20240516Open filing evidence
2022-01-01 – 2022-12-31308981796 KRW20240401Open filing evidence